Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Opioid Use Disorder
- Sponsor
- University of California, Los Angeles
- Enrollment
- 7554
- Locations
- 1
- Primary Endpoint
- Treatment Retention
- Status
- Completed
- Last Updated
- 4 months ago
Overview
Brief Summary
The aim of the study is to test the effectiveness of the Patient Decision Aid for Opioid Use Disorder (PtDA-MAT) by conducting a stepped-wedge cluster-randomized trial in CA H&SS (stratified by rural vs. non-rural areas) for adults with OUD. Patient outcomes will be tracked by (1) personal assessments (baseline, 3 months, and 6 months): drug use, overdose, healthcare utilization, and (2) clinical and administrative records (over approximately 24 months): drug treatment status and retention, physical and mental health diagnoses, arrest, incarceration, controlled substance use, and mortality. Multilevel models will be applied to test the intervention effects, controlling for possible temporal trends.
Detailed Description
In response to RFA-DA-18-005 (Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants, R21/R33), this project will develop and test a patient decision support tool called Patient Decision Aid for Medication-Assisted Treatment (PtDA-MAT) for use in the CA H\&SS. The PtDA-MAT is designed to (1) improve patient knowledge and involvement and to subsequently improve treatment adherence and outcomes and (2) to support clinicians in informing and communicating with their patients with OUD along a continuum of care. The 3 year project will assess the effectiveness of the PtDA-MAT in a stepped-wedge cluster-randomized trial in CA H\&SS (stratified by rural vs. non-rural areas) for adults with OUD. Patient outcomes will be tracked by (1) personal assessments (baseline, 3 months, and 6 months): drug use, overdose, healthcare utilization, and (2) clinical and administrative records (over an average of 24 months): drug treatment status and retention, physical and mental health diagnoses, arrest, incarceration, controlled substance use, and mortality. Multilevel models will be applied to test the intervention effects, controlling for possible temporal trends.
Investigators
Yih-Ing Hser
Professor-in-Residence
University of California, Los Angeles
Eligibility Criteria
Inclusion Criteria
- •Opioid Use Disorder diagnosis and agreement to follow study procedures (including permission to share medical records and other administrative records)
Exclusion Criteria
- •Significant or unstable medical or psychiatric illness that may interfere with study participation
Outcomes
Primary Outcomes
Treatment Retention
Time Frame: 24 months
Treatment retention will be defined as time from initial treatment admission to either MAT discontinuation or most recent clinic visit followed by 2 months gap in treatment
Opioid Use at 6 months
Time Frame: 6 months
Self-reported days of opioid use in past 4 weeks
Opioid Use at 3 months
Time Frame: 3 months
Self-reported days of opioid use in past 4 weeks
Secondary Outcomes
- Substance Use(24 months)
- Treatment Adherence(24 months)
- Mortality(24 months)